Rogers Corporation - NYSE:ROG - Comprehensive analysis
We believe the market has not fully recognized Roche's robust drug portfolio and its industry-leading diagnostics, which together create sustainable competitive advantages. The challenges posed by declining COVID diagnostic revenue and competition from generics and biosimilars for older drugs are diminishing as we approach 2025, allowing the strength of the firm's portfolio of market-leading drugs to come to the forefront. We also see that the firm's research and development expenditures are becoming more efficient, and recent acquisitions in obesity and immunology have the potential to generate multi-billion-dollar sales. As a leader in biotech and diagnostics, this Swiss healthcare giant is uniquely positioned to advance global healthcare towards a safer, more personalized, and cost-effective model. The synergy between its diagnostics and drug development teams provides Roche with a distinctive in-house perspective on personalized medicine. Furthermore, Roche's biologics represent three-quarters of its pharmaceutical sales; while biosimilar competitors have encountered development challenges, Roche's innovative pipeline may render these products less significant upon their launch.
Free evaluation through quantitative algorithms Rogers Corporation - NYSE:ROG
Growth-Scoring Model Detail
Total Revenue Growth Over Prior Year | -8.62 | Market 6 Sector 21 |
Gross Profit Growth Over Prior Year | -9.77 | Market 8 Sector 20 |
EBITDA Growth Over Prior Year | -22.9 | Market 6 Sector 18 |
EBITA Growth Over Prior Year | -31.74 | Market 6 Sector 17 |
EBIT Growth Over Prior Year | -35.99 | Market 5 Sector 16 |
Earnings from Cont. Ops. Growth Over Prior Year | -53.89 | Market 6 Sector 14 |
Net Income Growth Over Prior Year | -53.89 | Market 7 Sector 13 |
Normalized Net Income Growth Over Prior Year | -13.59 | Market 15 Sector 25 |
Diluted EPS before Extra Growth Over Prior Year | -53.8 | Market 6 Sector 13 |
A/R Growth Over Prior Year | -23.23 | Market 3 Sector 12 |
Inventory Growth Over Prior Year | -7.3 | Market 15 Sector 25 |
PPE Net Growth Over Prior Year | 1.04 | Market 46 Sector 55 |
Total Assets Growth Over Prior Year | -2.38 | Market 23 Sector 35 |
Tangible Book Value Growth Over Prior Year | 1.08 | Market 30 Sector 45 |
Common Equity Growth Over Prior Year | -0.59 | Market 32 Sector 38 |
Cash from Ops. Growth Over Prior Year | -3.27 | Market 36 Sector 29 |
CAPEX Growth Over Prior Year | -1.58 | Market 33 Sector 45 |
Dividend per Share Growth Over Prior Year | 0 | Market 36 Sector 45 |
Levered Free Cash Flow Growth Over Prior Year | 105 | Market 92 Sector 83 |
Unlevered Free Cash Flow Growth Over Prior Year | 84 | Market 89 Sector 81 |
Profitability-Scoring Model Detail
Gross Margin % | 33.4 | Market 31 Sector 26 |
SG&A Margin % | 23.3 | Market 72 Sector 36 |
EBITDA Margin % | 11.84 | Market 15 Sector 59 |
EBITA Margin % | 7.38 | Market 18 Sector 57 |
EBIT Margin % | 5.89 | Market 11 Sector 58 |
Earnings from Cont. Ops Margin % | 3.14 | Market 12 Sector 56 |
Net Income Margin % | 3.14 | Market 12 Sector 56 |
Net Income Avail. for Common Margin % | 3.14 | Market 13 Sector 57 |
Normalized Net Income Margin % | 4.4 | Market 16 Sector 62 |
Levered Free Cash Flow Margin % | 12.77 | Market 60 Sector 59 |
Unlevered Free Cash Flow Margin % | 12.85 | Market 56 Sector 56 |
Return on Assets % | 2.04 | Market 15 Sector 58 |
Return on Capital % | 2.36 | Market 13 Sector 56 |
Return on Equity % | 2.08 | Market 7 Sector 52 |
Return on Common Equity % | 2.08 | Market 7 Sector 52 |
Total Asset Turnover | 0.55 | Market 57 Sector 46 |
